Chronic Myeloid Leukemia Chronic Myeloid Leukemia, BCR-ABL1, Molecular Monitoring, Precision Medicine
Conditions
Interventions
Patients diagnosed with Chronic Myeloid Leukemia (CML) who underwent BCR-ABL1 quantitative RT-PCR testing at Phrapokklao Hospital between January 2023 and June 2026. Clinical and laboratory data were
Treatment
Chronic Myeloid Leukemia Patients
Sponsors
Phrapokklao hospital,Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with Chronic Myeloid Leukemia (CML). , 2.Patients who underwent BCR-ABL1 quantitative RT-PCR testing at Phrapokklao Hospital. , 3. Patients who received BCR-ABL1 testing between January 2023 and June 2026. , 4. Patients with complete demographic, laboratory, and clinical data available in the Laboratory Information System (LIS), Hospital Information System (HIS), and medical records.
Exclusion criteria
Exclusion criteria: 1. Patients with incomplete laboratory or clinical records for data analysis. , 2.Patients whose BCR-ABL1 test results were unavailable, invalid, or could not be interpreted according to the International Scale (IS).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Access to BCR-ABL1 Molecular Monitoring During the study period Percentage of eligible CML patients who received BCR-ABL1 molecular monitoring | — |
Secondary
| Measure | Time frame |
|---|---|
| Turnaround Time (TAT) For each BCR-ABL1 test performed during the study period Number of days from specimen receipt to release of the BCR-ABL1 test report | — |
Countries
Thailand
Contacts
Public ContactChada Sartsuk
Genomics and Precision Medicine Laboratory, Phrapokklao Hospital
Outcome results
None listed